By Cole Petrochko, Staff Writer, MedPage Today

Patients may need help managing metabolic and endocrine disorders with healthy eating and lifestyle choices, and now there's a comprehensive set of clinical guidelines, issued jointly by the American Association of Clinical Endocrinologists, the American College of Endocrinology, and the Obesity Society, to assist them.

By Kristina Fiore, Staff Writer, MedPage Today
Reviewed by Zalman S. Agus, MD; Emeritus Professor, Perelman School of Medicine at the University of Pennsylvania and Dorothy Caputo, MA, BSN, RN, Nurse

Although control of the disease has improved over the past few decades, about a quarter of patients with acromegaly aren't hitting treatment targets, British researchers found.

By Salynn Boyles, Contributing Writer, MedPage Today
Reviewed by Zalman S. Agus, MD; Emeritus Professor, Perelman School of Medicine at the University of Pennsylvania and Dorothy Caputo, MA, BSN, RN, Nurse Planner

Treatment with the synthetic human hormone rhPTH(1-84) reduced the need for calcium and active vitamin D by at least 50% in more than half of patients with the rare endocrine disorder hypoparathyroidism, researchers reported.

Published by News-Medical.net

Over a quarter of UK patients treated for growth hormone-producing tumours do not achieve 'safe' growth hormone (GH) levels, according to a 30 year UK multi-centre study of clinical management of the rare disease acromegaly. The findings by the Society for Endocrinology UK Acromegaly Register, published in the November issue of Clinical Endocrinology, show that drugs to control acromegaly often fail to bring the disease completely under control in routine clinical practice.